These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 33313471)

  • 21. Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A.
    Pocoski J; Li N; Ayyagari R; Church N; Maas Enriquez M; Xiang Q; Kelkar S; Du EX; Wu EQ; Xie J
    J Blood Med; 2016; 7():129-37. PubMed ID: 27445511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy, safety and pharmacokinetics of recombinant human coagulation factor VIII (omfiloctocog alfa) in previously treated Chinese children with severe hemophilia A.
    Wu R; Wang X; Zhao X; Cheng Y; Zhou Z; Sun J; Xu M; Li W; Xiao J; Yang F; Chen Y; Xu W; Huang J; Ma C; Gai W; Xie L; Yang R
    Haemophilia; 2022 Nov; 28(6):e199-e208. PubMed ID: 35802040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Updates from guardian™: a comprehensive registration programme.
    Ozelo MC
    Eur J Haematol; 2015 Dec; 95 Suppl 81():22-9. PubMed ID: 26679394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new recombinant factor VIII: from genetics to clinical use.
    Santagostino E
    Drug Des Devel Ther; 2014; 8():2507-15. PubMed ID: 25548513
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1).
    Klamroth R; Feistritzer C; Friedrich U; Lentz SR; Reichwald K; Zak M; Chowdary P
    J Thromb Haemost; 2020 Feb; 18(2):341-351. PubMed ID: 31618804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy, safety, and immunogenicity of rurioctocog alfa pegol for prophylactic treatment in previously treated patients with severe hemophilia A: a systematic review and meta-analysis of clinical trials.
    Witarto BS; Visuddho V; Witarto AP; Sutanto H; Wiratama BS; Wungu CDK
    F1000Res; 2021; 10():1049. PubMed ID: 35136579
    [No Abstract]   [Full Text] [Related]  

  • 27. An Open-label, Single-dose, Pharmacokinetic Study of Factor VIII Activity After Administration of Moroctocog Alfa (AF-CC) in Male Chinese Patients With Hemophilia A.
    Liu H; Wu R; Hu P; Sun F; Xu L; Liang Y; Nepal S; Qu PR; Huard F; Korth-Bradley JM
    Clin Ther; 2017 Jul; 39(7):1313-1319. PubMed ID: 28601434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A.
    von Drygalski A; Chowdary P; Kulkarni R; Susen S; Konkle BA; Oldenburg J; Matino D; Klamroth R; Weyand AC; Jimenez-Yuste V; Nogami K; Poloskey S; Winding B; Willemze A; Knobe K;
    N Engl J Med; 2023 Jan; 388(4):310-318. PubMed ID: 36720133
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonacog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Moderately Severe or Severe Hemophilia B in India.
    Choraria N; Rangarajan S; John MJ; Apte S; Gupta P; Pai S; Chand R; Parvatini S; Ramakanth GSH; Rupon J; Chhabra A; Muley HB; Simoneau D
    Indian J Hematol Blood Transfus; 2023 Oct; 39(4):630-634. PubMed ID: 37790744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Turoctocog alfa (recombinant factor VIII). Manufacturing, characteristics and clinical trial results.
    Tiede A; Klamroth R; Oldenburg J
    Hamostaseologie; 2015; 35(4):364-71. PubMed ID: 26271775
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Effect of Fluctuating Temperature on the Stability of Turoctocog Alfa for Hemophilia A.
    Napolitano M; Nøhr AM
    Drugs R D; 2019 Dec; 19(4):381-390. PubMed ID: 31782067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A.
    Male C; Königs C; Dey S; Matsushita T; Millner AH; Zak M; Young G; Kenet G
    Blood Adv; 2023 Feb; 7(4):620-629. PubMed ID: 35858373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The immunogenicity, safety, and efficacy of N8-GP in previously untreated patients with severe hemophilia A: pathfinder6 end-of-trial results.
    Kenet G; Young G; Chuansumrit A; Matsushita T; Yadav V; Zak M; Male C
    J Thromb Haemost; 2023 Nov; 21(11):3109-3116. PubMed ID: 37597724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant FVIII Products (Turoctocog Alfa and Turoctocog Alfa Pegol) Stable Up to 40°C.
    Napolitano M; Olsen AA; Nøhr AM; Eichler H
    J Blood Med; 2021; 12():9-20. PubMed ID: 33536803
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Turoctocog alfa (NovoEight®)--from design to clinical proof of concept.
    Ezban M; Vad K; Kjalke M
    Eur J Haematol; 2014 Nov; 93(5):369-76. PubMed ID: 24797664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs.
    Agersø H; Stennicke HR; Pelzer H; Olsen EN; Merricks EP; Defriess NA; Nichols TC; Ezban M
    Haemophilia; 2012 Nov; 18(6):941-7. PubMed ID: 22812621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.
    Parra Lopez R; Nemes L; Jimenez-Yuste V; Rusen L; Cid AR; Charnigo RJ; Baumann JA; Smith L; Korth-Bradley JM; Rendo P
    Thromb Haemost; 2015 Oct; 114(4):676-84. PubMed ID: 26293201
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stability of Turoctocog Alfa, a Recombinant Factor VIII Product, during Continuous Infusion In Vitro.
    Takeyama M; Nøhr AM; Pollard D
    TH Open; 2020 Oct; 4(4):e354-e361. PubMed ID: 33195971
    [No Abstract]   [Full Text] [Related]  

  • 39. Safety and Efficacy of Moroctocog Alfa (AF-CC) in Chinese Patients with Hemophilia A: Results of Two Open-Label Studies.
    Yang R; Zhao Y; Wang X; Sun J; Wu R; Jin C; Jin J; Wu D; Rendo P; Sun F; Rupon J; Huard F; Korth-Bradley JM; Xu L; Luo B; Liu YC
    J Blood Med; 2020; 11():439-448. PubMed ID: 33269010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study.
    Sidonio RF; Thompson AA; Peyvandi F; Stasyshyn O; Yeoh SL; Sosothikul D; Antmen AB; Maggiore C; Engl W; Ewenstein B; Tangada S
    Expert Rev Hematol; 2023; 16(10):793-801. PubMed ID: 37646148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.